A recent landmark analysis compared genome-wide mutations and associated 'omics' features for 3,281 tumours across 12 human cancer types. There is a clear need for objective target assessment and prioritization by the drug discovery community to make the best use of such vast amounts of data.
- Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013). et al.
- Cancer genome landscapes. Science 339, 1546–1558 (2013). et al.
- A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004). et al.
- Objective assessment of cancer genes for drug discovery. Nature Rev. Drug Discov. 12, 35–50 (2013). et al.
- canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 40, D947–D956 (2012). et al.
- Supplementary information S1 (box) (1.96 MB)
Objective analysis of cancer genes